Managing Evaporative Dry Eye with New FDA-Approved Therapy

EP: 1.Overview of MGD and Its Causes

EP: 2.Differentiating Aqueous vs Evaporative Dry Eye

EP: 3.Long-Term Consequences of Untreated MGD

EP: 4.Factors to Consider in Treatment Selection for MGD

Now Viewing

EP: 5.Managing Evaporative Dry Eye with New FDA-Approved Therapy

EP: 6.Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye

EP: 7.Combining In-Office and At-Home Therapies

EP: 8.Clinical Case Scenario: Management Strategies for MGD and Key Takeaways

Video content above is prompted by the following questions:

• We now have the first FDA-approved treatment for evaporative dry eye [perfluorohexyloctane ophthalmic solution (MIEBO)]. What is significant about this new treatment?
  • Why do we need to target evaporative dry eye specifically?